Combination anastrozole and fulvestrant in metastatic breast cancer

New England Journal of Medicine

Volumn 367, Issue 5, 2012, Pages 435-444

  Mehta, Rita S ^a   Barlow, William E ^b   Albain, Kathy S ^d   Vandenberg, Ted A ^e   Dakhil, Shaker R ^f   Tirumali, Nagendra R ^g   Lew, Danika L ^b   Hayes, Daniel F ^h   Gralow, Julie R ^c   Livingston, Robert B ⁱ   Hortobagyi, Gabriel N ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c SEATTLE CANCER CARE ALLIANCE   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e Queen's Cancer Research Institute   (Canada)

^f WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^g Northwest CCOP/Northwest Permanente   (United States)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FULVESTRANT; HORMONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; METASTASIS; MUSCULOSKELETAL PAIN; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION;

EID: 84864512253     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1201622     Document Type: Article

References (28)

1. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006;98:1285-91. (Pubitemid 44530724)
2. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-73.
3. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-13. (Pubitemid 41079798)
4. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
5. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
6. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746-50.
7. Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 2008;68:3516-22.
8. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44. (Pubitemid 40827357)
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
10. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600. [Erratum, J Clin Oncol 2011;29:2293.]
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
12. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short term biological effects of 7alpha-[9-(4,4,5,5,5-pentaf luoropentylsulfinyl)- nonyl]estra-1,3,5(10)triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with breast cancer. Cancer Res 2001;61:6739-46. (Pubitemid 32896496)
13. Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5.
14. Rubens RD, Knight RK. The contribution of prednisolone (P) to primary endocrine therapy (PET) in advanced breast cancer. Proc Am Soc Clin Oncol 1985;4:53. abstract.
15. Rubens RD, Tinson CL, Coleman RE, et al. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 1988;58:626-30. (Pubitemid 19010715)
16. Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med 1983;98:139-44. (Pubitemid 13190908)
17. Ingle JN, Green SJ, Ahmann DL, et al. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 1986;4:958-64. (Pubitemid 16080950)
18. Ingle JN, Twito DI, Schaid DJ, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer: an updated analysis. Cancer 1991;67:886-91.
19. Russell CA, Green SJ, O'Sullivan J, et al. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol 1997;15:2494-501. (Pubitemid 27289877)
20. Goss P, Bondarenko IN, Manikhas GN, et al. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol 2007;25:4961-6. (Pubitemid 350220428)
21. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9. [Erratum, Lancet 2002;360:1520.] (Pubitemid 34694019)
22. Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012;30:1919-25.
23. Bonneterre J, Thürlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57. [Erratum, J Clin Oncol 2012;30:343.]
24. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000;18:3758-67.
25. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9. (Pubitemid 46606358)
26. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247-58.
27. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90.
28. Dawood S, Broglio K, Ensor J, Hortobagyi GN, Giordano SH. Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010;21:2169-74.